All Pharma News
price-trendAsk Us
Asana Bio Begins Dosing in Phase 1 Trial of ASN004

Asana Bio Begins Dosing in Phase 1 Trial of ASN004
BUSINESSWIRE
08 Apr 2022
Share Share
Asana to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b

Asana to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b
BUSINESSWIRE
22 Apr 2021
Share Share
Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema

Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema
BUSINESSWIRE
22 Apr 2021
Share Share
Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate
BUSINESSWIRE
03 Feb 2021
Share Share
Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2

Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2
BIOSPACE
22 Oct 2020
Share Share
Asana to Present Positive Results from Ph2b Study of Oral JAK/SYK Gusacitinib

Asana to Present Positive Results from Ph2b Study of Oral JAK/SYK Gusacitinib
BIOSPACE
20 Oct 2020
Share Share
Asana BioSciences Announces +ve Topline Results Ph2b Study Oral Gusacitinib

Asana BioSciences Announces +ve Topline Results Ph2b Study Oral Gusacitinib
TYAHOO
02 Jun 2020
Share Share
Asana BioSciences Announces Topline result Ph2b Study Oral JAK/SYK Gusacitinib

Asana BioSciences Announces Topline result Ph2b Study Oral JAK/SYK Gusacitinib
BUSINESSWIRE
02 Jun 2020
Share Share
Asana BioSciences Announce ASN008 Achieves Positive Results

Asana BioSciences Announce ASN008 Achieves Positive Results
BUSINESS WIRE
10 Mar 2020
Share Share
Amedisys acquires Asana Hospice

Amedisys acquires Asana Hospice
A. Bakshi SEEKING Alpha
26 Nov 2019
Share Share